Cases & Deals

  • Home
  • Practices
  • Cellectis completes $164 million follow-on public offering of American Depositary Shares on NASDAQ

Share

Cellectis completes $164 million follow-on public offering of American Depositary Shares on NASDAQ

April 2018

Client(s) Cellectis SA

Jones Day represented Cellectis S.A., a French clinical-stage biopharmaceutical developer of innovative cancer treatments using gene editing technologies, in connection with a $164 million public offering of American Depositary Shares on NASDAQ, underwritten by Goldman Sachs & Co. LLC, Citigroup, and Barclays.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.